40 related articles for article (PubMed ID: 15259031)
21. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
22. Immunogenic HLA-B7-restricted peptides of hTRT.
Cortez-Gonzalez X; Sidney J; Adotevi O; Sette A; Millard F; Lemonnier F; Langlade-Demoyen P; Zanetti M
Int Immunol; 2006 Dec; 18(12):1707-18. PubMed ID: 17077179
[TBL] [Abstract][Full Text] [Related]
23. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells.
Hernandez J; Garcia-Pons F; Lone YC; Firat H; Schmidt JD; Langlade-Demoyen P; Zanetti M
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12275-80. PubMed ID: 12218171
[TBL] [Abstract][Full Text] [Related]
24. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.
Gross DA; Graff-Dubois S; Opolon P; Cornet S; Alves P; Bennaceur-Griscelli A; Faure O; Guillaume P; Firat H; Chouaib S; Lemonnier FA; Davoust J; Miconnet I; Vonderheide RH; Kosmatopoulos K
J Clin Invest; 2004 Feb; 113(3):425-33. PubMed ID: 14755339
[TBL] [Abstract][Full Text] [Related]
25. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
[TBL] [Abstract][Full Text] [Related]
26. Telomerase immunity from bench to bedside: round one.
Cortez-Gonzalez X; Zanetti M
J Transl Med; 2007 Feb; 5():12. PubMed ID: 17324292
[TBL] [Abstract][Full Text] [Related]
27. Prospects and challenges of building a cancer vaccine targeting telomerase.
Vonderheide RH
Biochimie; 2008 Jan; 90(1):173-80. PubMed ID: 17716803
[TBL] [Abstract][Full Text] [Related]
28. Telomerase reverse transcriptase as target for anti-tumor T cell responses in humans.
Zanetti M; Hernandez X; Langlade-Demoyen P
Springer Semin Immunopathol; 2005 Jun; 27(1):87-104. PubMed ID: 15711953
[TBL] [Abstract][Full Text] [Related]
29. Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer.
Shaw VE; Naisbitt DJ; Costello E; Greenhalf W; Park BK; Neoptolemos JP; Middleton GW
Expert Rev Vaccines; 2010 Sep; 9(9):1007-16. PubMed ID: 20822343
[TBL] [Abstract][Full Text] [Related]
30. [Novel strategies for peptide-based immunotherapy: identification of peptide superagonists using combinatorial peptide libraries and mass spectrometry].
Matsushita S
Arerugi; 1999 Nov; 48(11):1200-5. PubMed ID: 10630018
[No Abstract] [Full Text] [Related]
31. Antigenicity and immunogenicity of peptide analogues of a low affinity peptide of the human telomerase reverse transcriptase tumor antigen.
Hernández J; Schoeder K; Blondelle SE; Pons FG; Lone YC; Simora A; Langlade-Demoyen P; Wilson DB; Zanetti M
Eur J Immunol; 2004 Aug; 34(8):2331-41. PubMed ID: 15259031
[TBL] [Abstract][Full Text] [Related]
32. The immunogenicity of the hTERT540-548 peptide in cancer.
Wenandy L; Sørensen RB; Sengeløv L; Svane IM; thor Straten P; Andersen MH
Clin Cancer Res; 2008 Jan; 14(1):4-7. PubMed ID: 18172245
[TBL] [Abstract][Full Text] [Related]
33. [Human telomerase reverse transcriptase as a novel target for tumor immunotherapy].
Pang JX
Ai Zheng; 2003 Aug; 22(8):893-5. PubMed ID: 12917043
[TBL] [Abstract][Full Text] [Related]
34. Cancer immunotherapy targeting the telomerase reverse transcriptase.
Huo LF; Tang JW; Huang JJ; Huang PT; Huang CF; Kung HF; Lin MC
Cell Mol Immunol; 2006 Feb; 3(1):1-11. PubMed ID: 16549043
[TBL] [Abstract][Full Text] [Related]
35. Telomerase as a universal tumor-associated antigen for cancer immunotherapy.
Vonderheide RH
Oncogene; 2002 Jan; 21(4):674-9. PubMed ID: 11850795
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
